Spero Therapeutics (SPRO) Non-Current Deffered Revenue (2016 - 2025)
Spero Therapeutics' (SPRO) quarterly Non-Current Deffered Revenue came in at $12.6 million in Q3 2025, up 6.12% YoY from $11.8 million in Q3 2024, and little changed on a QoQ basis from $12.6 million in Q2 2025.
Spero Therapeutics (SPRO) Non-Current Deffered Revenue (2016 - 2025) Analysis & Trends
Spero Therapeutics (SPRO) has 8 years of Non-Current Deffered Revenue data on file, last reported at $12.6 million in Q3 2025.
- Quarterly Non-Current Deffered Revenue rose 6.12% year-over-year to $12.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $12.6 million (up 6.12% YoY) and the FY2024 annual result came in at $12.2 million, up 12.88% from the prior year.
- Non-Current Deffered Revenue held at $12.6 million in Q3 2025, from $12.6 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $23.8 million in Q3 2023 to a low of $8.8 million in Q4 2021.
- A 5-year average of $13.5 million and a median of $12.2 million in 2024 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue sank 59.46% — and 2025, when it surged 39.1%.
- Tracing SPRO's Non-Current Deffered Revenue over 5 years: stood at $8.8 million in 2021, then gained by 10.87% to $9.7 million in 2022, then climbed by 11.13% to $10.8 million in 2023, then gained by 12.88% to $12.2 million in 2024, then advanced by 2.91% to $12.6 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $12.6 million (Q3 2025), $12.6 million (Q2 2025), and $12.6 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 12.58 Mn |
| Jun 30, 2025 | 12.58 Mn |
| Mar 31, 2025 | 12.58 Mn |
| Dec 31, 2024 | 12.22 Mn |
| Sep 30, 2024 | 11.85 Mn |
| Jun 30, 2024 | 9.04 Mn |
| Mar 31, 2024 | 9.95 Mn |
| Dec 31, 2023 | 10.83 Mn |
| Sep 30, 2023 | 23.75 Mn |
| Jun 30, 2023 | 22.30 Mn |
| Mar 31, 2023 | 19.95 Mn |
| Dec 31, 2022 | 9.74 Mn |
| Dec 31, 2021 | 8.79 Mn |
| Dec 31, 2018 | 833,000.00 |
| Sep 30, 2018 | 290,000.00 |
| Jun 30, 2018 | 323,000.00 |
| Mar 31, 2018 | 327,000.00 |
| Dec 31, 2017 | 365,000.00 |
| Sep 30, 2017 | 399,000.00 |
| Dec 31, 2016 | 493,000.00 |